

DENTISTRY & DENTAL MARKETING

&

ORAL CARE & ORAL CANCER

October 24- 25, 2018 | Boston, USA

Transdermal nanostructured STE Roi DS replacement therapy: Novel protocol for TMJ disorders

Melissa Kelly Senedin
Senedin Clinical, Brazil

Temporomandibular joint dysfunction (TMD), which limits muscle function, has a significant impact on quality of life, may present as a pain that often limits function and sometimes is accompanied by a decrease in the opening of the mouth, pain, buccal locking: Closed or opening. The intrauterine device (IUD) with levonorgestrel, is used in birth control, heavy menstrual periods and to prevent excessive build-up of the lining of the uterus in estrogen replacement therapy with levonorgestrel hormone, leads to a hormonal decompensating, with serious consequences for women, such as: increased risk of Deep Venous Thrombosis (DVT), pulmonary embolism, increased risk of myocardial infarction and other side effects. Steroid hormones perform various functions throughout the body as well as the stomatognathic system, contributing to the improvement of pain and inflammation. Rebalancing them allows you to return the proper physiology to the patient. Studies show that millions of women in the world use contraceptive method with progestogen hormones, one of them is the intrauterine device with levonorgestrel, in which they present a significant increase of the risk in all its organism, by its systemic action due to the inhibition of hypothalamus-pituitary axis and ovary, as action maintains the levels of LH (Luteinizing hormone) and FSH: Follicle Stimulating Hormone. The new proposed protocol for TMJ pain and mobility, which consisted in the removal of Diu Mirena and replacement of steroidal nanoemulsion hormones with progesterone, testosterone and vitamin D3, proved to be effective, as it significantly restored serum levels of patients.

Biography

Melissa Kelly Senedin has completed her MS in health biotechnology from Potiguar University and postgraduate in implant and endodontics. She is the owner Senedin Clinical, since 2001.

melissasenedin@gmail.com

Notes: